STAT News

Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.

By STAT News

1 min read
Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights